The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.

@article{Marcus2008TheEA,
  title={The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.},
  author={Ronald N. Marcus and Robert D. McQuade and William H. Carson and Delphine Hennicken and Maurizio Fava and Jeffrey S. Simon and Madhukar H. Trivedi and Michael E. Thase and Robert M. Berman},
  journal={Journal of clinical psychopharmacology},
  year={2008},
  volume={28 2},
  pages={156-65}
}
Nonresponse to one or more antidepressants is common and an important public health problem. This study evaluated the efficacy and safety of adjunctive aripiprazole or placebo to standard antidepressant therapy (ADT) in patients with major depressive disorder who showed an inadequate response to at least 1 and up to 3 historical and 1 additional prospective ADT. The study comprised a 7-28-day screening, an 8-week prospective treatment, and a 6-week randomization phase. During prospective… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 109 extracted citations

Similar Papers

Loading similar papers…